Treatment of Severe Infections Due to Metallo-Betalactamases <i>Enterobacterales</i> in Critically Ill Patients
Metallo-beta-lactamases-producing (MBL) <i>Enterobacterales</i> is a growing problem worldwide. The optimization of antibiotic therapy is challenging. The pivotal available therapeutic options are either the combination of ceftazidime/avibactam and aztreonam or cefiderocol. Colistin, fos...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-01-01
|
| Series: | Antibiotics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-6382/11/2/144 |
| _version_ | 1827657604802805760 |
|---|---|
| author | Jean-François Timsit Paul-Henri Wicky Etienne de Montmollin |
| author_facet | Jean-François Timsit Paul-Henri Wicky Etienne de Montmollin |
| author_sort | Jean-François Timsit |
| collection | DOAJ |
| description | Metallo-beta-lactamases-producing (MBL) <i>Enterobacterales</i> is a growing problem worldwide. The optimization of antibiotic therapy is challenging. The pivotal available therapeutic options are either the combination of ceftazidime/avibactam and aztreonam or cefiderocol. Colistin, fosfomycin, tetracyclines and aminoglycosides are also frequently effective in vitro, but are associated with less bactericidal activity or more toxicity. Prior to the availability of antibiotic susceptibility testing, severe infections should be treated with a combination therapy. A careful optimization of the pharmacokinetic/pharmacodynamic properties of antimicrobials is instrumental in severe infections. The rules of antibiotic therapy are also reported and discussed. To conclude, treatment of severe MBL infections in critically ill patients is difficult. It should be individualized with a close collaboration of intensivists with microbiologists, pharmacists and infection control practitioners. |
| first_indexed | 2024-03-09T22:47:21Z |
| format | Article |
| id | doaj.art-630c408a982a4f4ba160bf827599de6e |
| institution | Directory Open Access Journal |
| issn | 2079-6382 |
| language | English |
| last_indexed | 2024-03-09T22:47:21Z |
| publishDate | 2022-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antibiotics |
| spelling | doaj.art-630c408a982a4f4ba160bf827599de6e2023-11-23T18:27:09ZengMDPI AGAntibiotics2079-63822022-01-0111214410.3390/antibiotics11020144Treatment of Severe Infections Due to Metallo-Betalactamases <i>Enterobacterales</i> in Critically Ill PatientsJean-François Timsit0Paul-Henri Wicky1Etienne de Montmollin2APHP, Service de Médecine Intensive et Réanimation Infectieuse, Hôpital Bichat Claude-Bernard, 46 Rue Henri Huchard, 75018 Paris, FranceAPHP, Service de Médecine Intensive et Réanimation Infectieuse, Hôpital Bichat Claude-Bernard, 46 Rue Henri Huchard, 75018 Paris, FranceAPHP, Service de Médecine Intensive et Réanimation Infectieuse, Hôpital Bichat Claude-Bernard, 46 Rue Henri Huchard, 75018 Paris, FranceMetallo-beta-lactamases-producing (MBL) <i>Enterobacterales</i> is a growing problem worldwide. The optimization of antibiotic therapy is challenging. The pivotal available therapeutic options are either the combination of ceftazidime/avibactam and aztreonam or cefiderocol. Colistin, fosfomycin, tetracyclines and aminoglycosides are also frequently effective in vitro, but are associated with less bactericidal activity or more toxicity. Prior to the availability of antibiotic susceptibility testing, severe infections should be treated with a combination therapy. A careful optimization of the pharmacokinetic/pharmacodynamic properties of antimicrobials is instrumental in severe infections. The rules of antibiotic therapy are also reported and discussed. To conclude, treatment of severe MBL infections in critically ill patients is difficult. It should be individualized with a close collaboration of intensivists with microbiologists, pharmacists and infection control practitioners.https://www.mdpi.com/2079-6382/11/2/144metallo-beta-lactamasessepsiscritically illaztreonamcefiderocolavibactam |
| spellingShingle | Jean-François Timsit Paul-Henri Wicky Etienne de Montmollin Treatment of Severe Infections Due to Metallo-Betalactamases <i>Enterobacterales</i> in Critically Ill Patients Antibiotics metallo-beta-lactamases sepsis critically ill aztreonam cefiderocol avibactam |
| title | Treatment of Severe Infections Due to Metallo-Betalactamases <i>Enterobacterales</i> in Critically Ill Patients |
| title_full | Treatment of Severe Infections Due to Metallo-Betalactamases <i>Enterobacterales</i> in Critically Ill Patients |
| title_fullStr | Treatment of Severe Infections Due to Metallo-Betalactamases <i>Enterobacterales</i> in Critically Ill Patients |
| title_full_unstemmed | Treatment of Severe Infections Due to Metallo-Betalactamases <i>Enterobacterales</i> in Critically Ill Patients |
| title_short | Treatment of Severe Infections Due to Metallo-Betalactamases <i>Enterobacterales</i> in Critically Ill Patients |
| title_sort | treatment of severe infections due to metallo betalactamases i enterobacterales i in critically ill patients |
| topic | metallo-beta-lactamases sepsis critically ill aztreonam cefiderocol avibactam |
| url | https://www.mdpi.com/2079-6382/11/2/144 |
| work_keys_str_mv | AT jeanfrancoistimsit treatmentofsevereinfectionsduetometallobetalactamasesienterobacteralesiincriticallyillpatients AT paulhenriwicky treatmentofsevereinfectionsduetometallobetalactamasesienterobacteralesiincriticallyillpatients AT etiennedemontmollin treatmentofsevereinfectionsduetometallobetalactamasesienterobacteralesiincriticallyillpatients |